BRPI0108923B8 - elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina - Google Patents

elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina

Info

Publication number
BRPI0108923B8
BRPI0108923B8 BR0108923A BR0108923A BRPI0108923B8 BR PI0108923 B8 BRPI0108923 B8 BR PI0108923B8 BR 0108923 A BR0108923 A BR 0108923A BR 0108923 A BR0108923 A BR 0108923A BR PI0108923 B8 BRPI0108923 B8 BR PI0108923B8
Authority
BR
Brazil
Prior art keywords
specific binding
binding member
eotaxin
antibody
methods
Prior art date
Application number
BR0108923A
Other languages
English (en)
Other versions
BR0108923A (pt
BRPI0108923B1 (pt
Inventor
Jane Wilton Alison
Helen Main Sarah
Smith Stephen
John Vaughan Tristan
Original Assignee
Cambridge Antibody Tech Limited
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Tech Limited, Medimmune Ltd filed Critical Cambridge Antibody Tech Limited
Publication of BR0108923A publication Critical patent/BR0108923A/pt
Publication of BRPI0108923B1 publication Critical patent/BRPI0108923B1/pt
Publication of BRPI0108923B8 publication Critical patent/BRPI0108923B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina. elementos de ligação específicos dirigidos para eotaxina-1, particularmente anticorpos humanos e fragmentos de anticorpos contra eotaxina -1 humana e especialmente os que neutralizam atividade de eotaxina-1. os domínios vh e/ou vl de anticorpos de fg scfv, aqui chamado cat- 212 e os de anticorpo igg4, aqui chamados cat 213. uma ou mais regiões de determinação complementares (cdrs) de domínios vh e/ou vl de cat212/213, especialmente vh crd3, em outras regiões de armação de anticorpos. composições contendo elementos de ligação específicos e seu uso em métodos para inibir ou neutralizar eotaxina, incluindo métodos de tratamento do corpo humano ou animal por terapia.
BR0108923A 2000-03-03 2001-03-02 elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina BRPI0108923B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18724600P 2000-03-03 2000-03-03
PCT/GB2001/000927 WO2001066754A1 (en) 2000-03-03 2001-03-02 Human antibodies against eotaxin and their use

Publications (3)

Publication Number Publication Date
BR0108923A BR0108923A (pt) 2003-04-22
BRPI0108923B1 BRPI0108923B1 (pt) 2018-11-13
BRPI0108923B8 true BRPI0108923B8 (pt) 2021-05-25

Family

ID=22688187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108923A BRPI0108923B8 (pt) 2000-03-03 2001-03-02 elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina

Country Status (14)

Country Link
US (6) US7323311B2 (pt)
EP (1) EP1259615B1 (pt)
JP (1) JP5198704B2 (pt)
AT (1) ATE414151T1 (pt)
AU (1) AU778392B2 (pt)
BR (1) BRPI0108923B8 (pt)
CA (1) CA2401342C (pt)
DE (1) DE60136527D1 (pt)
GB (1) GB2361704C (pt)
IL (2) IL151499A0 (pt)
MX (1) MXPA02008472A (pt)
NO (1) NO20024179L (pt)
NZ (1) NZ521182A (pt)
WO (1) WO2001066754A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
JP2005509412A (ja) 2001-08-23 2005-04-14 アールエスアール リミテッド チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
CN104151427B (zh) 2005-02-08 2017-09-08 根茨美公司 针对TGFβ的抗体
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
SI1942939T2 (sl) 2005-09-30 2021-11-30 Medimmune Limited Sestavek protitelesa proti interlevkinu-13
DK1999152T3 (da) 2006-03-27 2013-01-14 Medimmune Ltd Bindende element til gm-csf-receptor
RU2016142225A (ru) 2009-05-13 2018-12-18 Джензим Корпорейшн Иммуноглобулины к cd52 человека
US8176867B2 (en) 2009-05-28 2012-05-15 Richard J. A. Gayton Watercraft immobilizing system
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
AU2011329647B2 (en) 2010-11-19 2015-10-22 Eisai R&D Management Co., Ltd. Neutralizing anti-CCL20 antibodies
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
KR102261618B1 (ko) 2015-03-31 2021-06-04 메디뮨 리미티드 신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
MX2018008939A (es) 2016-01-22 2019-08-21 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulacion xi.
EP4000632A1 (en) 2016-06-02 2022-05-25 MedImmune Limited Antibodies to alpha-synuclein and uses thereof
WO2017212488A1 (en) * 2016-06-06 2017-12-14 Hadasit Medical Research Service And Development Ltd. Anti-eotaxin for immunoprotection and hepatoprotection
MY201852A (en) 2016-06-14 2024-03-20 Merck Sharp & Dohme Llc Anti-coagulation factor xi antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
EP0523949B1 (en) * 1991-07-15 2003-06-25 The Wellcome Foundation Limited Production of antibodies
IL103758A (en) 1991-12-13 1998-07-15 Akzo Nv Cancer-specific monoclonal antibodies
DE69434878T3 (de) * 1993-09-14 2014-07-17 Imperial Innovations Ltd. Eotaxin = eosinophil chemotaktisches cytokin
US6403782B1 (en) 1995-06-22 2002-06-11 President And Fellows Of Harvard College Nucleic acid encoding eotaxin
US7265201B1 (en) 1995-06-23 2007-09-04 Millennium Pharmaceuticals, Inc. Human chemotactic cytokine
AU7097696A (en) * 1995-10-05 1997-04-28 Shionogi & Co., Ltd. Novel human cc chemokine
WO1999010534A1 (en) 1997-08-22 1999-03-04 Center For Blood Research, Inc. Diagnosis and treatment of diseases with eotaxin and antagonists and agonists thereof
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO1999066951A2 (en) * 1998-06-22 1999-12-29 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
ATE414151T1 (de) 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20080182319A1 (en) 2008-07-31
ATE414151T1 (de) 2008-11-15
IL151499A0 (en) 2003-04-10
US20040014132A1 (en) 2004-01-22
EP1259615B1 (en) 2008-11-12
CA2401342A1 (en) 2001-09-13
DE60136527D1 (de) 2008-12-24
JP5198704B2 (ja) 2013-05-15
JP2003528598A (ja) 2003-09-30
GB2361704C (en) 2006-08-02
US9284589B2 (en) 2016-03-15
MXPA02008472A (es) 2004-03-26
GB2361704B (en) 2002-04-10
GB0105237D0 (en) 2001-04-18
IL151499A (en) 2010-06-30
NO20024179D0 (no) 2002-09-02
NO20024179L (no) 2002-11-01
CA2401342C (en) 2010-08-03
AU778392B2 (en) 2004-12-02
WO2001066754A1 (en) 2001-09-13
US7323311B2 (en) 2008-01-29
US20210277103A1 (en) 2021-09-09
US20140294857A1 (en) 2014-10-02
NZ521182A (en) 2004-11-26
US10577413B2 (en) 2020-03-03
US20160257741A1 (en) 2016-09-08
US20120270265A1 (en) 2012-10-25
AU3585201A (en) 2001-09-17
BR0108923A (pt) 2003-04-22
BRPI0108923B1 (pt) 2018-11-13
EP1259615A1 (en) 2002-11-27
US8715961B2 (en) 2014-05-06
GB2361704A (en) 2001-10-31
US8067564B2 (en) 2011-11-29

Similar Documents

Publication Publication Date Title
BRPI0108923B8 (pt) elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
HRP20160270T1 (hr) Monoklonska antitijela protiv glipikana-3
HRP20161338T1 (hr) Limfocitni antigen
BRPI0611414B8 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos
CY1115671T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
BRPI0407833A (pt) anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio
HRP20060033A2 (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
PT2305715T (pt) Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
BRPI0611984A2 (pt) uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
DE60031279D1 (de) Humane monoklonale antikörper gegen prostata spezifisches membranantigen
BRPI0214137B8 (pt) anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo
ATE482722T1 (de) Therapeutische verwendung von anti-cs1- antikörpern
BRPI0513078C1 (pt) anticorpo igg que se liga a il-17 humana e composição líquida
DK1504035T3 (da) Antistoffer, der er specifikke for human CD22, og deres terapeutiske og diagnostiske anvendelser
DK3284753T3 (da) Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
BRPI0614040B8 (pt) anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
NO20083053L (no) Humane monoklonale antistoffer mot O8E
BR0306808A (pt) Anticorpos monoclonais humanos contra cd30
ECSP024402A (es) Anticuerpos para mcp-1 humana
BR0207068A (pt) Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
WO2004046306A3 (en) Fully human antibody fab fragments with human interferon-gamma neutralizing activity
ATE435239T1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
WO2002059154A3 (en) Neutralizing human monoclonal antibodies against hiv-1, their production and uses

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 15/13 , C12N 15/62 , C12N 5/10 , C07K 16/24

Ipc: C07K 16/24 (2006.01), C12N 15/19 (2006.01), C12N 1

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: MEDIMMUNE LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: MEDIMMUNE LIMITED (GB)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 02/03/2021